American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025
Molecular Profiling of Genes Associated With Methylphenidate Pathway Therapy and Discovery of New Variants in Amazonian Amerindian Populations.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Santos Aline Pasquini, de Souza Tatiane Carinta, Aguiar Kaio Evandro Cardoso, da Costa Ana Caroline Alves, Monte Natasha, Rodrigues Juliana Carla Gomes, Nunes Giovanna Gilioli da Costa, Coelho Rita de Cássia Calderaro, Ribeiro-Dos-Santos Ândrea, Dos Santos André Maurício Ribeiro, de Souza Sandro José, Dos Santos Sidney Emanuel Batista, Burbano Rommel Mario Rodriguez, Fernandes Marianne Rodrigues, Dos Santos Ney Pereira Carneiro
Аннотация
In Attention Deficit Hyperactivity Disorder (ADHD), methylphenidate is one of the most widely used drugs, in which patient response significantly impacts prognosis. This study aimed to characterize the molecular profile of 10 genes associated with methylphenidate therapy. Whole-exome sequencing of 64 indigenous individuals from 12 different indigenous populations in the Amazon was used. A total of 143 genetic variants were identified, of which 123 were analyzed. Among these, three novel and population-specific variants were found, all with modifying impact, located in the ADGRL3 and ADRA2A genes. In addition, we identified a high-impact variant in the COMT gene, which exhibited statistical significance in the INDG population compared to other groups, along with five variants with moderate impact and 31 with modifying impact. Our findings highlight the unique genetic profile of indigenous populations in the Brazilian Amazon and provide valuable insights to optimize ADHD management and treatment strategies. This study contributes to improving therapeutic responses to methylphenidate and supports the development of precision medicine guidelines.